Shiga toxin binding to glycolipids and glycans

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Gallegos, Karen M ^a   Conrady, Deborah G ^a   Karve, Sayali S ^a   Gunasekera, Thusitha S ^a   Herr, Andrew B ^a   Weiss, Alison A ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE; CHOLESTEROL; GLOBOTETRAOSYLCERAMIDE; GLOBOTRIAOSYLCERAMIDE; GLYCAN; GLYCOLIPID; GLYCOSPHINGOLIPID; PHOSPHATIDYLCHOLINE; SHIGA TOXIN; UNCLASSIFIED DRUG; VEROTOXIN 1; VEROTOXIN 2; POLYSACCHARIDE;

ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ISOTHERMAL TITRATION CALORIMETRY; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; VERO CELL; METABOLISM; PROTEIN BINDING;

GLYCOLIPIDS; POLYSACCHARIDES; PROTEIN BINDING; SHIGA TOXIN; SHIGA TOXIN 1; SHIGA TOXIN 2;

EID: 84856936344     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030368     Document Type: Article

References (62)

1. CDC (2005) Enterohemorrhagic Escherichia coli. National Center for Zoonotic, Vector-Borne, and Enteric Diseases Atlanta Centers for Disease Control and Prevention.
2. Bitzan M, (2009) Treatment options for HUS secondary to Escherichia coli O157:H7. Kidney Int 75: S62-S66.
3. Whyte DA, Fine RN, (2008) Chronic kidney disease in children. Pediat in Rev 29: 335-341.
4. Hughes AK, Stricklett PK, Schmid D, Kohan DE, (2000) Cytotoxic effect of Shiga toxin-1 on human glomerular epithelial cells1. Kidney Int 57: 2350-2359.
5. Okuda T, Tokuda N, Numata S-i, Ito M, Ohta M, et al. (2006) Targeted disruption of Gb3/CD77 synthase gene resulted in the complete deletion of globo-series glycosphingolipids and loss of sensitivity to verotoxins. J Biol Chem 281: 10230-10235.
6. Shimizu T, Sato T, Kawakami S, Ohta T, Noda M, et al. (2007) Receptor affinity, stability and binding mode of Shiga toxins are determinants of toxicity. Microb Pathog 43: 88-95.
7. Shin I-S, Ishii S, Shin J-S, Sung K-I, Park B-S, et al. (2009) Globotriaosylceramide (Gb3) content in HeLa cells is correlated to Shiga toxin-induced cytotoxicity and Gb3 synthase expression. BMB reports 42: 310-314.
8. Endo Y, Tsurugi K, Yutsudo T, Takeda Y, Ogasawara T, et al. (1988) Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. Eur J Biochem 171: 45-50.
9. Obrig TG, Moran TP, Brown JE, (1987) The mode of action of Shiga toxin on peptide elongation of eukaryotic protein synthesis. Biochem J 244: 287-294.
10. Tesh VL, O'Brien AD, (1991) The pathogenic mechanisms of Shiga toxin and the Shiga-like toxins. Mol Microbiol 5: 1817-1822.
11. Kozlov YV, Kabishev AA, Lukyanov EV, Bayev AA, (1988) The primary structure of the operons coding for Shigella dysenteriae toxin and temperate phage H30 Shiga-like toxin. Gene 67: 213-221.
12. Fuller CA, Pellino CA, Flagler MJ, Strasser JE, Weiss AA, (2011) Shiga toxin subtypes display dramatic differences in potency. Infect Immun 79: 1329-1337.
13. Rutjes NWP, Binnington BA, Smith CR, Maloney MD, Lingwood CA, (2002) Differential tissue targeting and pathogenesis of verotoxins 1 and 2 in the mouse animal model. Kidney Int 62: 832-845.
14. Tesh VL, Burris JA, Owens JW, Gordon VM, Wadolkowski EA, et al. (1993) Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice. Infect Immun 61: 3392-3402.
15. Head SC, Karmali MA, Lingwood CA, (1991) Preparation of VT1 and VT2 hybrid toxins from their purified dissociated subunits. Evidence for B subunit modulation of a subunit function. J Biol Chem 266: 3617-3621.
16. Flagler MJ, Mahajan SS, Kulkarni AA, Iyer SS, Weiss AA, (2010) Comparison of binding platforms yields insights into receptor binding differences between Shiga toxins 1 and 2. Biochem 49: 1649-1657.
17. Weinstein DL, Jackson MP, Perera LP, Holmes RK, O'Brien AD, (1989) In vivo formation of hybrid toxins comprising Shiga toxin and the Shiga-like toxins and role of the B subunit in localization and cytotoxic activity. Infect Immun 57: 3743-3750.
18. Lingwood CA, (1996) Role of verotoxin receptors in pathogenesis. Trends microbiol 4: 147-153.
19. Armstrong GD, Mulvey GL, Marcato P, Griener TP, Kahan MC, et al. (2006) Human serum amyloid P component protects against Escherichia coli O157:H7 Shiga toxin 2 in vivo: therapeutic implications for Hemolytic-Uremic Syndrome. J Infec Dis 193: 1120-1124.
20. Ling H, Boodhoo A, Hazes B, Cummings MD, Armstrong GD, et al. (1998) Structure of the Shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3. Biochem 37: 1777-1788.
21. Cummings MD, Ling H, Armstrong GD, Brunton JL, Read RJ, (1998) Modeling the carbohydrate-binding specificity of pig edema toxin. Biochem 37: 1789-1799.
22. Ling H, Pannu NS, Boodhoo A, Armstrong GD, Clark CG, et al. (2000) A mutant Shiga-like toxin IIe bound to its receptor Gb3: structure of a group II Shiga-like toxin with altered binding specificity. Structure 8: 253-264.
23. Nakajima H, Kiyokawa N, Katagiri YU, Taguchi T, Suzuki T, et al. (2001) Kinetic analysis of binding between Shiga toxin and receptor glycolipid Gb3Cer by surface plasmon resonance. J Biol Chem 276: 42915-42922.
24. Kale RR, McGannon CM, Fuller-Schaefer C, Hatch DM, Flagler MJ, et al. (2008) Differentiation between structurally homologous Shiga 1 and Shiga 2 toxins by using synthetic glycoconjugates. Angewandte Chemie Int Ed 47: 1265-1268.
25. Miura Y, Sasao Y, Dohi H, Nishida Y, Kobayashi K, (2002) Self-assembled monolayers of globotriaosylceramide (Gb3) mimics: surface-specific affinity with shiga toxins. Anal Biochem 310: 27-35.
26. Flagler MJ, (2010) Determination of the molecular basis for the difference in potency between Shiga Toxins 1 and 2 Cincinnati, OH University of Cincinnati.
27. Kulkarni AA, Weiss AA, Iyer SS, (2010) Glycan-based high-affinity ligands for toxins and pathogen receptors. Med Res Rev 30: 327-393.
28. Waddell T, Head S, Petric M, Cohen A, Lingwood C, (1988) Globotriosyl ceramide is specifically recognized by the Escherichia coli verocytotoxin 2. Biochem and Biophys Res Commun 152: 674-679.
29. DeGrandis S, Law H, Brunton J, Gyles C, Lingwood CA, (1989) Globotetraosylceramide is recognized by the pig edema disease toxin. J Biol Chem 264: 12520-12525.
30. Zumbrun SD, Hanson L, Sinclair JF, Freedy J, Melton-Celsa AR, et al. (2010) Human Intestinal tissue and cultured colonic cells contain globotriaosylceramide synthase mRNA and the alternate Shiga toxin receptor, globotetraosylceramide. Infect Immun 78: 4488-4499.
31. Rinaldi S, Brennan KM, Goodyear CS, O'Leary C, Schiavo G, et al. (2009) Analysis of lectin binding to glycolipid complexes using combinatorial glycoarrays. Glycobiol 19: 789-796.
32. Jacobson K, Mouritsen OG, Anderson RGW, (2007) Lipid rafts: at a crossroad between cell biology and physics. Nat Cell Biol 9: 7-14.
33. Risselada HJ, Marrink SJ, (2008) The molecular face of lipid rafts in model membranes. Proc Natl Acad Sci 105: 17367-17372.
34. St. Hilaire PM, Boyd MK, Toone EJ, (1994) interaction of the Shiga-like toxin type 1 B-subunit with its carbohydrate receptor. Biochem 33: 14452-14463.
35. Kitova EN, Kitov PI, Paszkiewicz E, Kim J, Mulvey GL, et al. (2007) Affinities of Shiga toxins 1 and 2 for univalent and oligovalent Pk-trisaccharide analogs measured by electrospray ionization mass spectrometry. Glycobiol 17: 1127-1137.
36. Binnington B, Lingwood D, Nutikka A, Lingwood CA, (2002) Effect of globotriaosyl ceramide fatty acid α-hydroxylation on the binding by Verotoxin 1 and Verotoxin 2. Neurochem Res 27: 807-813.
37. Lingwood CA, Binnington B, Manis A, Branch DR, (2010) Globotriaosyl ceramide receptor function - Where membrane structure and pathology intersect. FEBS letters 584: 1879-1886.
38. Boyd B, Magnusson G, Zhiuyan Z, Lingwood CA, (1994) Lipid modulation of glycolipid receptor function. Eur J Biochem 223: 873-878.
39. Donohue-Rolfe A, Acheson DWK, Keusch GT, (1991) Shiga Toxin: purification, structure, and function. Rev Infect Dis 13: S293-S297.
40. Wen SX, Teel LD, Judge NA, O'Brien AD, (2006) Genetic toxoids of Shiga toxin types 1 and 2 protect mice against homologous but not heterologous toxin challenge. Vaccine 24: 1142-1148.
41. Millen SH, Lewallen DM, Herr AB, Iyer SS, Weiss AA, (2010) Identification and characterization of the carbohydrate ligands recognized by pertussis toxin via a glycan microarray and surface plasmon resonance. Biochem 49: 5954-5967.
42. Lewallen DM, Siler D, Iyer SS, (2009) Factors affecting protein-glycan specificity: Effect of spacers and incubation time. ChemBioChem 10: 1486-1489.
43. Heinrich L, Tissot N, Hartmann DJ, Cohen R, (2010) Comparison of the results obtained by ELISA and surface plasmon resonance for the determination of antibody affinity. J Immun Methods 352: 13-22.
44. Norton WT, Abe T, Poduslo SE, DeVries GH, (1975) The lipid composition of isolated brain cells and axons. J Neurosci Res 1: 57-75.
45. Ogawa-Goto K, Abe T, (1998) Gangliosides and glycosphingolipids of peripheral nervous system myelins-a Minireview. Neurochem Res 23: 305-310.
46. Basta M, Karmali M, Lingwood C, (1989) Sensitive receptor-specified Enzyme-Linked Immunosorbent Assay for Escherichia coli verocytotoxin. J Clin Microbiol 27: 1617-1622.
47. Takenaga M, Igarashi R, Higaki M, Nakayama T, Yuki K, et al. (2000) Effect of a soluble pseudo-receptor on Verotoxin 2-induced toxicity. J Infect Chemother 6: 21-25.
48. Boulanger J, Petric M, Lingwood C, Law H, Roscoe M, et al. (1990) Neutralization receptor-based immunoassay for detection of neutralizing antibodies to Escherichia coli verocytotoxin 1. J Clin Microbiol 28: 2830-2833.
49. Kim Y-H, Cha I-H, Cho H-H, Kim SH, Jin H-K, et al. (1996) Distribution of Verocytotoxin- producing Escherichia coli and development of receptor binding Enzyme- Linked Immunosorbent Assay 2. Korean J Vet Public Health 20: 55.
50. Pellizzari A, Pang H, Lingwood CA, (1992) Binding of verocytotoxin 1 to its receptor is influenced by differences in receptor fatty acid content. Biochem 31: 1363-1370.
51. Khan F, Proulx F, Lingwood CA, (2009) Detergent-resistant globotriaosyl ceramide may define verotoxin/glomeruli-restricted Hemolytic Uremic Syndrome pathology. Kidney Int 75: 1209-1216.
52. Yahi N, Aulas A, Fantini J, (2010) How cholesterol constrains glycolipid conformation for optimal recognition of Alzheimer's β amyloid peptide (Aβ1-40). PLoS ONE 5: e9079.
53. Lingwood D, Binnington B, Róg T, Vattulainen I, Grzybek M, et al. (2011) Cholesterol modulates glycolipid conformation and receptor activity. Nat Chem Biol 7: 260-262.
54. Mahfoud R, Manis A, Binnington B, Ackerley C, Lingwood CA, (2010) A major fraction of glycosphingolipids in model and cellular cholesterol-containing membranes is undetectable by their binding proteins. J Biol Chem 285: 36049-36059.
55. Hammache D, Piéroni G, Yahi N, Delézay O, Koch N, et al. (1998) Specific interaction of HIV-1 and HIV-2 Surface envelope glycoproteins with monolayers of galactosylceramide and ganglioside GM3. J Biol Chem 273: 7967-7971.
56. Scheiring J, Andreoli S, Zimmerhackl L, (2008) Treatment and outcome of Shiga-toxin-associated Hemolytic Uremic Syndrome (HUS). Pediatr Nephrol 23: 1749-1760.
57. Katagiri YU, Mori T, Nakajima H, Katagiri C, Taguchi T, et al. (1999) Activation of Src family kinase YES induced by shiga toxin binding to globotriaosyl ceramide (Gb3/CD77) in low density, detergent-insoluble microdomains. J Biol Chem 274: 35278-35282.
58. Liu F, Huang J, Sadler JE, (2011) Shiga toxin (Stx)1B and Stx2B induce von Willebrand factor secretion from Human Umbilical Vein Endothelial Cells through different signaling pathways. Blood 118: 3392-3398.
59. Huang J, Motto DG, Bundle DR, Sadler JE, (2010) Shiga toxin B subunits induce VWF secretion by Human Endothelial Cells And Thrombotic Microangiopathy in ADAMTS13-deficient mice. Blood 116: 3653-3659.
60. Palermo MS, Exeni RA, Fernandez GC, (2009) Hemolytic Uremic Syndrome: pathogenesis and update of interventions.(Report). Expert Rev Anti-infect Ther 7: 697-707.
61. Conrady DG, Flagler MJ, Friedmann DR, Vander Wielen BD, Kovall RA, et al. (2010) Molecular basis of differential B-pentamer stability of Shiga toxins 1 and 2. PLoS ONE 5: e15153.
62. McGannon CM, Fuller CA, Weiss AA, (2010) Different classes of antibiotics differentially influence Shiga toxin production. Antimicrob Ag Chemother 54: 3790-3798.